Lorna Ewart is currently Head of Strategy and Enabling Services in AstraZeneca's Drug Safety and Metabolism function and is based in Cambridge. Her current role is to ensure successful externalisation of all safety and metabolism studies through key strategic partners as well as smaller contract research organisations and/or academics. She also oversees the data and information integration for the function as well as capacity and resource management. Lorna has set a strategy for the function and is managing its implementation via scientific collaborations and key stakeholder inputs. More recently she has been leading a team across innovative medicines exploring the future of drug discovery and development with a particular focus on translational models such as microphysiological systems. Lorna has over 17 years' experience in the pharmaceutical industry primarily in the respiratory and inflammation therapy area. She has a unique blend of experience driving the efficacy (pharmacology) and safety (toxicology and metabolism) aspects of drug discovery and development. She received her honours degree in Pharmacology from the University of Aberdeen and her PhD at the William Harvey Research Institute, London.
Navigating Tissue Chips from Development to Dissemination: A Pharmaceutical Industry Perspective
Add to Calendar ▼2017-05-10 00:00:002017-05-11 00:00:00Europe/LondonLab-on-a-Chip and Microfluidics 2017Lab-on-a-Chip and Microfluidics 2017 in Holiday Inn City Centre, Munich, GermanyHoliday Inn City Centre, Munich, GermanySELECTBIOenquiries@selectbiosciences.com